Role of SGLT2 inhibitors in cancer therapy-related cardiac dysfunction (CTRCD) in adults: systematic review and meta-analysis: SGLT2 inhibitors and CTRCD
Naunyn-Schmiedeberg's Archives of Pharmacology · 2026-01 · 399 (1) · 1197-1210
DOI: 10.1007/s00210-025-04489-x ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 01.08.2025. Verfasst von Gustavo Adolfo Vásquez-Tirado und 10 weiteren Autor:innen. Beteiligte Einrichtung: Facultad de Medicina, Universidad Privada Antenor Orrego, Trujillo, Perú. gavt13@gmail.com. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Neoplasms, Diabetes Mellitus, Type 2, Antineoplastic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
Our primary objective is to evaluate the role of SGLT2 inhibitors in the protection against cancer therapy-related cardiac dysfunction (CTRCD) in adults with both cancer and type 2 diabetes mellitus. This is a systematic review and meta-analysis. A comprehensive search was conducted in five databases for studies published up to January 5th, 2025, using a PECO strategy. Seven studies were identified for quantitative analysis and included in our meta-analysis. Primary studies evaluating the use of SGLT2 inhibitors for the protection against CTRCD were included, specifically those in which CTRCD developed after chemotherapy and without a prior history of heart failure as the primary outcome. In the meta-analysis of 10,460 patients who received SGLT2i versus 12,815 in the control group, we found that SGLT2i use was associated with a 48% reduction in the risk of developing CTRCD (RR 0.52; 95% CI: 0.30-0.90; I2: 31%). Additionally, there was a reduction in both all-cause mortality (RR 0.44; 95% CI: 0.31-0.63; I2: 90%) and acute kidney injury (AKI) as a complication (RR 0.61; 95% CI: 0.49-0.77; I2: 0%). The use of SGLT2i in patients with cancer and T2DM may reduce the risk of CTRCD, mortality, and AKI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Facultad de Medicina, Universidad Privada Antenor Orrego, Trujillo, Perú. gavt13@gmail.com.
- Unidad de Cuidados Intensivos, Hospital Regional Docente de Trujillo, Trujillo, Perú. gavt13@gmail.com.
- Escuela de Posgrado, Universidad Señor de Sipán, Chiclayo, Perú.
- Facultad de Medicina, Universidad Privada Antenor Orrego, Trujillo, Perú.
- Facultad de Medicina, Universidad Nacional de Trujillo, Trujillo, Perú.
- Unidad de Cuidados Intensivos, Hospital Regional Docente de Trujillo, Trujillo, Perú.
Zitieren
APA
Vásquez-Tirado, G. A., Meregildo-Rodríguez, E. D., Quispe-Castañeda, C. V., Guzmán-Aguilar, W. M., Liñán-Díaz, L. J., Abanto-Montalván, P. H., Serna-Alarcón, V., Alva-Guarniz, H., Ortiz-Pizarro, M., Rodríguez-Chávez, L. Á., & Cuadra-Campos, M. (2026). Role of SGLT2 inhibitors in cancer therapy-related cardiac dysfunction (CTRCD) in adults: systematic review and meta-analysis: SGLT2 inhibitors and CTRCD. Naunyn-Schmiedeberg's Archives of Pharmacology, 399(1), 1197-1210. https://doi.org/10.1007/s00210-025-04489-x
Vancouver
Vásquez-Tirado GA, Meregildo-Rodríguez ED, Quispe-Castañeda CV, Guzmán-Aguilar WM, Liñán-Díaz LJ, Abanto-Montalván PH, et al. Role of SGLT2 inhibitors in cancer therapy-related cardiac dysfunction (CTRCD) in adults: systematic review and meta-analysis: SGLT2 inhibitors and CTRCD. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026;399(1):1197-1210. doi:10.1007/s00210-025-04489-x
BibTeX
@article{VsquezTirado2026,
author = {Vásquez-Tirado, Gustavo Adolfo and Meregildo-Rodríguez, Edinson Dante and Quispe-Castañeda, Claudia Vanessa and Guzmán-Aguilar, Wilson Marcial and Liñán-Díaz, Leslie Jacqueline and Abanto-Montalván, Percy Hernán and Serna-Alarcón, Víctor and Alva-Guarniz, Hugo and Ortiz-Pizarro, Mariano and Rodríguez-Chávez, Luis Ángel and Cuadra-Campos, María},
title = {Role of SGLT2 inhibitors in cancer therapy-related cardiac dysfunction (CTRCD) in adults: systematic review and meta-analysis: SGLT2 inhibitors and CTRCD},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
volume = {399},
number = {1},
pages = {1197--1210},
doi = {10.1007/s00210-025-04489-x}
}
EUVIMED